<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108936</url>
  </required_header>
  <id_info>
    <org_study_id>15-101-0357</org_study_id>
    <nct_id>NCT04108936</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses</brief_title>
  <acronym>CRS/HIPEC</acronym>
  <official_title>Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Krankenhaus Barmherzige Brüder, Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With
      Peritoneal Carcinomatoses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cross-sectional and longitudinal analysis of cellular immune responses in the context of
      disease outcome.

      Cross-sectional and longitudinal analysis of the microbiome in the context of disease
      outcome.

      Analysis of renal function with respect of different HIPEC regimens

      Identification of clinical surrogate parameters for outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Prospective analysis of disease free after CRS/HIPEC for peritoneal carcinomatosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Prospective analysis of overall survival after CRS/HIPEC for peritoneal carcinomatosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function (serum creatinine (mg/dl))</measure>
    <time_frame>Before as well as during the first 7 days postoperative</time_frame>
    <description>Screening for acute renal insufficiency by measuring serum chemistry (serum creatinine (mg/dl) before as well as during the first 7 postoperative days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (urea (mg/dl))</measure>
    <time_frame>Before as well as during the first 7 days postoperative</time_frame>
    <description>Screening for acute renal insufficiency by measuring serum chemistry (serum urea (mg/dl) before as well as during the first 7 days postoperative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (urine output (ml/24h))</measure>
    <time_frame>Before as well as during the first 7 days postoperative</time_frame>
    <description>Screening for acute renal insufficiency by measuring urine output (ml/24h) before as well as during the first 7 postoperative days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome (Bacterial 16S ribosomal RNA gene sequences will be amplified, sequenced, and analyzed in comparison to publicly available data obtained from healthy volunteers)</measure>
    <time_frame>Before as well as at postoperative day 2 and 7</time_frame>
    <description>Longitudinal analysis of the microbial burden within samples will be quantified with droplet digital polymerase chain reaction. Bacterial 16S ribosomal RNA gene sequences will be amplified, sequenced, and analyzed in comparison to publicly available data obtained from healthy volunteers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular immune response (Frequency of NK cell subpopulations within lymphocyte populations measured by flow cytometry)</measure>
    <time_frame>Before as well as at postoperative day 2 and 7</time_frame>
    <description>Longitudinal analysis of cellular immune responses in blood and peritoneal tissue by flow cytometry. Measuring frequency of NK cell populations within total lymphocyte population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Questionnaire-WHOQOL-BREF)</measure>
    <time_frame>Before surgery and through study completion, an average of 3 years</time_frame>
    <description>Prospective analysis of quality of life after CRS/HIPEC for peritoneal carcinomatosis. Questionnaire-WHOQOL-BRE produces a quality of life profile. It is possible to derive four domain scores. There are also two items that are examined separately: question 1 asks about an individual's overall perception of quality of life and question 2 asks about an individual's overall perception of their health. The four domain scores denote an individual's perception of quality of life in each particular domain (Physical health (Score 7-35), Psychological (Score 6-30), Social relationships (Score 3-15), Environment (Score 8-40)). Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). The mean score of items within each domain is used to calculate the domain score transformed to 4-20 or 20-100.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Peritoneal Carcinomatosis</arm_group_label>
    <description>Patients suffering from Peritoneal carcinomatoses from either CRC, gastric cancer or primary peritoneal malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients suffering from CRC or gastric cancer without peritoneal carcinomatosis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples; stool samples; tumor samples; Peritoneal tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspicious peritoneal carcinomatosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suspicious peritoneal carcinomatosis

        Exclusion Criteria:

          -  &lt;18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Hornung, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Surgery, University Hospital Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Hauer, MD</last_name>
    <phone>+49 941 944</phone>
    <phone_ext>6801</phone_ext>
    <email>Patricia.Hauer@ukr.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens M Werner, MD</last_name>
    <phone>+49 941 944</phone>
    <phone_ext>6801</phone_ext>
    <email>Jens.Werner@ukr.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pompiliu Piso, MD</last_name>
      <phone>+49 941 3692201</phone>
      <email>pompiliu.piso@barmherzige-regensburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Hornung, MD</last_name>
      <phone>+49 941 944 6832</phone>
      <email>matthias.hornung@ukr.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens M Werner, MD</last_name>
      <phone>+49 941 944 6944</phone>
      <email>jens.werner@ukr.de</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Hauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011 Jan 7;331(6013):44-9. doi: 10.1126/science.1198687. Review.</citation>
    <PMID>21212348</PMID>
  </reference>
  <reference>
    <citation>Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Review.</citation>
    <PMID>24531241</PMID>
  </reference>
  <reference>
    <citation>Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.</citation>
    <PMID>21074069</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011 Oct 24;11(11):805-12. doi: 10.1038/nrc3153. Review.</citation>
    <PMID>22020206</PMID>
  </reference>
  <reference>
    <citation>Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013 Aug;1(2):85-91. doi: 10.1158/2326-6066.CIR-13-0078. Epub 2013 Jul 22. Review.</citation>
    <PMID>24777499</PMID>
  </reference>
  <reference>
    <citation>Miller JF, Sadelain M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 2015 Apr 13;27(4):439-49. doi: 10.1016/j.ccell.2015.03.007. Epub 2015 Apr 6. Review.</citation>
    <PMID>25858803</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Hans J Schlitt, Prof. MD</investigator_full_name>
    <investigator_title>Head of Surgery</investigator_title>
  </responsible_party>
  <keyword>CRS</keyword>
  <keyword>HIPEC</keyword>
  <keyword>cellular immune response</keyword>
  <keyword>microbiomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

